Clinical Trial Update: Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines [Phase 3]

View source ↗

Summary

Phase 3 trial results for daxibotulinumtoxinA for injection show efficacy and safety in treating moderate to severe glabellar lines, with completed status and p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines

Drugs mentioned

• DaxibotulinumtoxinA for Injection (daxibotulinumtoxinA)

Snippet

Sponsor: Revance Therapeutics, Inc. | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED | Results posted: 2022-07-21